Hyperglycemia and Lactic Acidosis Associated with Linezolid Therapy in an Extremely Premature Infant

Neonatology. 2022;119(6):781-784. doi: 10.1159/000526702. Epub 2022 Sep 30.

Abstract

The use of linezolid is relatively safe for all age categories, including premature infants. The case of an extremely premature infant with hyperglycemia and lactic acidosis associated with linezolid is reported. A 350-g male infant was born at 24 weeks by cesarean section. His Apgar scores were 1 and 1 at 1 and 5 min, respectively. On the day of life (DOL) 7, linezolid was started at a dose of 10 mg/kg/dose every 8 h for a catheter-related blood stream infection caused by methicillin-resistant coagulase-negative Staphylococci. After linezolid was given, serum lactate and glucose levels increased gradually. After discontinuation of linezolid on DOL 16, hyperglycemia and lactic acidosis improved immediately. In conclusion, a rare case of an extremely premature infant with hyperglycemia and lactic acidosis associated with linezolid was reported. It is crucial to monitor glucose levels along with lactate and pH levels during linezolid therapy.

Keywords: Extremely premature infant; Hyperglycemia; Lactic acidosis; Linezolid.

Publication types

  • Case Reports

MeSH terms

  • Acidosis, Lactic* / chemically induced
  • Cesarean Section
  • Female
  • Glucose
  • Humans
  • Infant, Extremely Premature
  • Infant, Newborn
  • Lactic Acid
  • Linezolid / adverse effects
  • Male
  • Pregnancy

Substances

  • Linezolid
  • Lactic Acid
  • Glucose